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Abstract: Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as 
almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels 
of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for 
improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the 
treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient 
outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two 
prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single 
agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse 
events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of 
bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients 
with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab 
in managing GBM.
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Introduction
Glioblastoma (GBM) is the most lethal subtype of 
glioma  (classified  as  a  World  Health  Organization 
Grade 4 infiltrative glioma) and is associated with 
a  median  survival  of  approximately  18  months.1 
Responses  to  treatment  are  seen  in  less  than  10% 
of  patients  with  recurrent  GBM,  and  the  median 
progression-free survival (PFS) is estimated at 9–10 
weeks  for  patients  with  recurrent  GBM.4  In  2005, 
a  randomized  phase  3  trial  demonstrated  that  the 
addition of temozolomide (TMZ) to adjuvant radiation 
therapy followed by 6-months of post-radiotherapy 
TMZ  was  associated  with  an  improvement  in  the 
median  survival  of  patients  with  newly  diagnosed 
GBM, from 12.1 months to 14.6 months.1,3 While this 
treatment regimen is now the standard of therapy for 
GBM, there is still no clearly established standard 
of  care  for  recurrent  GBM  albeit  both  carmustine 
implants  ie,  Gliadel  (requiring  a  reoperation  for 
insertion) and bevacizumab have been demonstrated 
in clinical trials to provide benefit and at least in the 
United States are approved for this indication.
Essentially  all  GBM  recur  after  initial  therapy, 
and the majority of patients do not survive beyond 
1  year  after  diagnosis  of  recurrent  disease  (1-year 
survivorship  is  approximately  20%–25%).4,6,7 
In historical phase 2 trials utilizing a variety of biologic 
and chemotherapy-based therapies in patients with 
recurrent  GBM,  response  rates  were  5%–9%,  and 
6-month PFS (PFS-6) rates ranged between 9% and 
28% (median 15%).4–7
Because  re-operation  and  re-radiation  are  treat-
ment  options  for  only  a  minority  of  patients,  the 
majority of patients with recurrent GBM are offered 
chemotherapy (investigational or best available) at the 
time of progression. Data from several clinical trials 
including three prospective studies have established 
antiangiogenic  therapy  with  the  humanized  anti–
vascular  endothelial  growth  factor  (anti-VEGF) 
monoclonal antibody bevacizumab (Avastin®; Genen-
tech,  South  San  Francisco,  CA),  with  or  without 
cytotoxic chemotherapy, as an active treatment option 
for  patients  with  recurrent  GBM  who  have  failed 
previous TMZ and radiation therapy,8 leading to the 
recent  US  Food  and  Drug  Administration  (FDA) 
approval of single-agent bevacizumab in previously 
treated GBM.9 This review will provide an overview 
of the role of angiogenesis in GBM, the development 
of  bevacizumab  treatment  for  recurrent  GBM,  the 
clinical  efficacy  and  safety  data  of  bevacizumab 
in  this  cancer  setting,  insights  into  bevacizumab 
administration,  and  a  projection  on  future  use  of 
bevacizumab in the treatment of GBM.
Angiogenesis and Glioblastoma
Angiogenesis  is  the  process  by  which  new  blood 
vessels form from existing vasculature by endothelial 
cell migration and proliferation. While angiogenesis is 
a natural physiologic process (ie, in placental growth, 
wound healing and menses), it is also required for 
tumor growth beyond 0.125 mm owing to the limits 
of oxygen and nutrient diffusion.10 Antiangiogenic 
strategies are effective in the treatment of cancer, 
in  part,  because  of  the  accessibility  and  genetic 
stability  of  endothelial  cells  (recognizing  this  is 
controversial with the recent understanding of tumor 
cell integration into the tumor vasculature), the fact 
that angiogenesis is largely absent in healthy adults 
allowing for therapeutic selectivity, and the residence 
of  cancer  stem  cells  in  the  (potentially  targeted) 
microvascular niche.11
Glioblastoma  is  one  of  the  most  vascularized 
cancers,12 and many preclinical studies use GBM 
as a tumor model of angiogenesis.13 VEGF is an 
important regulator of angiogenesis that is highly 
expressed  within  brain  tumors;14  in  GBM,  the 
highest  levels  of  VEGF  expression  are  seen  in 
areas of necrosis and relative hypoxia and regions 
of  endothelial  proliferation.15,16  The  degree  of 
both vasculature density and VEGF expression is 
correlated with the grade and biologic aggressiveness 
of gliomas (highest in GBM), as well as with clinical 
outcomes.17–20
The antiangiogenic agents that were first evaluated 
in  GBM  included  the  oral  inhibitors  thalidomide, 
lenalidomide  (an  analog  of  thalidomide),  and 
carboxyamidotriazole, as well as the copper-chelating 
drug  penicillamine.  The  results  with  these  first-
generation antiangiogenic therapies, however, were 
disappointing showing no additional clinical benefit 
compared to the standard of care (nitrosourea-based 
chemotherapy), weak inhibition of VEGF-mediated 
angiogenesis, and a lack of survival benefit.21–25 As a 
consequence more recent investigations have focused 
on newer, more potent angiogenic inhibitors such as 
bevacizumab.Bevacizumab for recurrent glioblastoma
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Bevacizumab Use in Glioblastoma
The addition of bevacizumab to standard chemother-
apy was initially shown to produce significant clinical 
benefit (PFS or overall survival [OS]) in patients with 
metastatic colorectal cancer, advanced non–small cell 
lung cancer, and metastatic breast cancer.26–29 These 
early trials excluded patients with untreated central 
nervous system (CNS) metastases due to concern for 
treatment-related  intracranial  hemorrhage.  However 
the clinical activity in other solid tumors and the need 
for improved therapy in patients with recurrent GBM 
resulted in the conduct of a small pilot study using a 
drug regimen similar to that used for colorectal cancer 
demonstrating  considerable  activity  (43%  objective 
response rate) and apparent safety with the combination 
of bevacizumab and irinotecan (Camptosar). As well, 
a recent meta-analysis reported that patients with CNS 
metastases treated with bevacizumab had low rates of 
tumor-associated  CNS  hemorrhage  consistent  with 
historical rates in this patient population, providing 
further evidence of the safety of bevacizumab in treat-
ing brain cancers.30,31 Bevacizumab was first evaluated 
in  recurrent  high-grade  gliomas  including  GBM  in 
combination with irinotecan, a topoisomerase I inhib-
itor, owing to its activity with irinotecan-containing 
regimens in patients with metastatic colorectal cancer.26 
These encouraging results prompted the investigation 
of  bevacizumab  with  irinotecan  in  subsequent  pro-
spective phase 2 studies.32–37 Several mechanisms of 
action have been suggested for the anti-GBM effect 
of bevacizumab, including direct inhibition of tumor-
associated  angiogenesis,  a  direct  anti-GBM  effect 
on  VEGF  receptor-expressing  GBM  cells,  disrup-
tion of the glioma stem cell microvascular niche, and 
improved vascular function or normalization.13,39,42,44 
The glioma stem cell microvascular niche may rep-
resent an important target of antiangiogenic agents, 
because the resident glioma stem cells are a popula-
tion of CD133+, nestin+, self-renewing, multipotent 
GBM-initiating  cells  that  are  relatively  radio-  and 
chemoresistant.38,39
Efficacy of Bevacizumab
Combination therapy for recurrent 
glioblastoma
At present, the available data for efficacy of bevaci-
zumab in GBM is derived from several Phase 2 and 
multiple retrospective studies (Table 1). In the first 
completed, prospectively designed, single institution, 
phase  2  trial  of  bevacizumab  and  irinotecan  for 
recurrent GBM, 20 of 35 (57%) patients had at least 
a  partial  response  (PR),  and  the  PFS-6  rate  was 
46%  (95%  confidence  interval  [CI],  32%–66%).33 
The  multicenter,  randomized,  non-comparative 
phase  2  BRAIN  study  (Genentech  sponsored) 
evaluating bevacizumab with or without irinotecan 
in  recurrent  TMZ-experienced  GBM  reported  an 
investigator determined response rate of 38% (31/82) 
with combination therapy, with a median duration of 
response of 4.3 months.34 The combination of beva-
cizumab and irinotecan was associated with a PFS-6 
rate of 50% and a median OS of 8.7 months (95% 
CI, 7.8–10.9 months).34 In retrospective   analyses and 
additional phase 2 studies, investigator determined 
response rates with bevacizumab-based combination 
therapy  have  ranged  between  19%  and  62%,  and 
PFS-6  rates  have  ranged  between  30%  and  46% 
in  patients  with  recurrent  GBM,  representing  an 
apparent and significant improvement compared with 
historical outcomes.31,32,37,46,47 An apparent improve-
ment (50%) in median OS (ranging from 31 weeks to 
42 weeks) has also been observed with bevacizumab-
based regimens relative to historical controls.33,34,46,47 
In a recent pilot study, the combination of bevaci-
zumab  and  concurrent  radiotherapy  (re-radiation) 
was shown to be active and well tolerated in recur-
rent malignant glioma.48 In this study, patients with 
recurrent GBM (n = 20) were treated with bevaci-
zumab and hypo  fractionated stereotactic radiotherapy 
(HSFRT) with an overall response rate of 50%, PFS-6 
of 65%, and median OS of 12.5 months. These results 
suggested (as has in vitro laboratory data) a possible 
clinical synergy of radiotherapy and bevacizumab and 
further suggested potential negative consequences of 
  re-radiation ie, radiation necrosis may be mitigated 
by concurrent administration of bevacizumab.
Single agent bevacizumab therapy  
for recurrent glioblastoma
In  addition  to  its  activity  when  combined  with 
irinotecan,  bevacizumab  has  also  been  shown  to 
increase  response  and  PFS  when  administered 
as  a  single  agent  in  patients  with  recurrent  GBM 
(Table  1).9,34,36  In  the  phase  2  BRAIN  study  of 
patients  with  GBM  who  relapsed  after  TMZ  and 
radiation treatment, the objective response rate with Chamberlain
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single-agent bevacizumab was 28% (24/85), with a 
median duration of response of 5.6 months.34 When 
responses in this study were calculated on the basis 
of MacDonald response criteria (including stable or 
improved clinical assessment as well as steroid dose) 
by  an  independent  radiology  review,  25.9%  (95% 
CI, 17.0%–36.1%) of patients were found to have 
responded to bevacizumab monotherapy.9 The PFS-6 
rate  with  single-agent  bevacizumab  was  42.6% 
(95% CI, 29.6%–55.5%), and the median OS was 
9.2 months (95% CI, 8.2–10.7 months).34 In the single 
institution,  prospective  phase  2  NCI  06-C-0064E 
study of 48 patients with recurrent GBM treated with 
single-agent bevacizumab, 71% and 35% of patients 
achieved radiographic response based on Levin and 
MacDonald criteria, respectively.36 When employing 
an outside and independent response assessment, the 
objective response rate was 19.6% (11/56; 95% CI, 
10.9%–31.3%).9 The median PFS was 16 weeks (95% 
CI, 12–26 weeks), the PFS-6 rate was 29% (95% CI, 
18%–48%), and the median OS was 31 weeks (95% 
CI, 21–54 weeks).36 The response data established by 
the BRAIN and NCI 06-C-0064E studies resulted in 
the FDA accelerated approval of single-agent beva-
cizumab for patients with recurrent GBM following 
prior upfront, TMZ-based chemoradiotherapy. Two 
additional studies (a prospective phase 2 trial and a 
retrospective  analysis)  have  also  evaluated  single-
agent bevacizumab in recurrent GBM with response 
rates of 25% and 42%, and PFS-6 rates of 32% and 
42%, respectively further supporting the activity of 
bevacizumab  for  recurrent  GBM.49,50  Nonetheless 
and as demonstrated by the European drug regulatory 
agency,  EMEA  (European  Medicines  Agency), 
approval  of  bevacizumab  for  recurrent  GBM  is 
dependent upon interpretation of the above mentioned 
data. European regulatory agencies were unconvinced 
by these studies and consequently, bevacizumab was 
not approved in Europe for this indication. It was 
suggested following completion of bevacizumab vs. 
an active control treatment such as a nitrosourea in a 
prospective randomized trial, further consideration of 
approval of bevacizumab for this indication would be 
entertained.
Safety Profile of Bevacizumab
In  general,  bevacizumab  treatment  is  generally 
well tolerated in patients with recurrent GBM, and 
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the    bevacizumab-related  toxicities  are  comparable 
to those that have been characterized in other solid 
cancers. Reported rates of grade 3 or higher adverse 
events with bevacizumab in patients with recurrent 
GBM  have  ranged  between  18%  and  66%,  and  it 
appears  that  the  rate  of  serious  treatment-related 
adverse  events  is  lower  when  bevacizumab  is 
used  as  a  single  agent.34,36,37,49  In  the  randomized, 
non-comparative phase 2 BRAIN study in patients 
with recurrent GBM, the rate of grade 3 or higher 
adverse events was 46% in patients treated with bev-
acizumab monotherapy and 66% in patients treated 
with bevacizumab plus irinotecan.34 Cross-trial com-
parisons also suggest that single-agent bevacizumab is 
associated with a lower rate of grade 3 adverse events 
than bevacizumab-containing combinations for GBM; 
however, these observations are subject to differences 
in study design and patient populations.37,49
The most common adverse events attributable to 
bevacizumab  treatment  in  recurrent  GBM  include 
low-grade  bleeding  (ie,  epistaxis),  hypertension, 
impaired wound healing, and proteinuria,32–34 which 
are  similar  to  bevacizumab  associated  toxicities 
in  other  cancer  types.26,28,29  The  majority  of  these 
toxicities  appear  to  be  due  to  on-target,  class-
specific actions of angiogenic inhibition, and reflect 
disruption  of  VEGF  in  normal  tissue.  The  rates 
of  serious  adverse  events  such  as  gastrointestinal 
perforation, reversible posterior leukoencephalopathy 
syndrome (RPLS), cardiac failure, and wound-healing 
complications in GBM studies are low (each #2% 
incidence).31–34,46,48,50,53  While  the  reported  rate  of 
grade 2 or higher bleeding events has been as high 
as  5.3%,  life-threatening  intracranial  hemorrhages 
have  occurred  in  only  a  small  percentage  (#3%) 
of  patients  treated  with  bevacizumab.31–34,37,46,50 
This latter incidence rate falls within the expected 
range for spontaneous events in patients with GBM 
(approximately  2%–3%).54,55  Relatively  high  rates 
of thromboembolism ie, deep vein thrombosis and 
pulmonary embolism have been reported in studies 
evaluating  bevacizumab-containing  therapy  in 
recurrent GBM (ranging from 1.6%–12.5%). However, 
these rates must be considered in the context of the 
significant risk of thromboembolism that is inherent 
in  patients  with  GBM.56  Thus,  the  cumulative 
data  from  clinical  trials  suggest  that  despite  small 
risks  of  life-threatening  complications,  including 
intracranial  hemorrhages  and  thromboembolism, 
bevacizumab-containing  therapy  is  well  tolerated 
with manageable, class-specific toxicities.
practical Issues Regarding 
Bevacizumab Administration
There  are  a  number  of  practical  issues  related  to 
treatment  administration,  combination  therapy, 
contraindications  and  other  safety-related  issues, 
response  evaluation,  and  disease  course  that  are 
relevant  to  the  use  of  bevacizumab  for  GBM. 
With  regard  to  administration,  the  recommended 
dose  and  schedule  of  single-agent  bevacizumab  is 
10 mg/kg intravenously every 2 weeks in patients 
with recurrent GBM.9 While most studies in recurrent 
GBM have evaluated bevacizumab (in combination 
with irinotecan) on a schedule of 10 mg/kg every 
2 weeks or a weekly equivalent dose of 15 mg/kg 
every 3 weeks, it is not clear what the ideal treatment 
schedule or dosage of bevacizumab should be because 
no direct comparisons of different treatment schedules 
or  dose-response  studies  have  been  conducted.57,58 
Consequently, until a benefit in efficacy or tolerability 
has  been  established  with  an  alternative  dosing 
regimen, bevacizumab should be administered as a 
single agent according to the prescribing information, 
at a dose of 10 mg/kg every 2 weeks.
It is also unclear as to which therapeutic agent, 
if  any,  should  be  combined  with  bevacizumab 
to  improve  efficacy  in  recurrent  GBM.  The 
similar  response  and  PFS-6  rates  observed  with 
bevacizumab monotherapy relative to bevacizumab 
plus  chemotherapy  (predominantly  irinotecan  but 
also  including  carboplatin,  BCNU,  CCNU,  TMZ, 
fotemustine,  erlotinib,  and  etoposide),  combined 
with the limited single-agent activity of irinotecan 
in  recurrent  GBM,  have  led  many  but  not  all 
investigators and the FDA to argue that it is unclear 
whether  irinotecan  (or  other  agents)  contributes 
additional  clinical  benefit  to  bevacizumab-based 
regimens in recurrent GBM.36,59–65 For these reasons, 
as well as the observation of higher rates of grade 3 
or higher adverse events that are associated with the 
combination  of  chemotherapy  and  bevacizumab, 
the addition of irinotecan or other agents outside of 
clinical trials does not appear to be justified at this 
time. The identification of an alternative partner for 
bevacizumab is currently an active area of research. Bevacizumab for recurrent glioblastoma
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As  an  example,  in Australia,  a  randomized  phase 
2 study (the Cabaret trial) is comparing bevacizumab 
with or without carboplatin to determine if there is 
any benefit to using carboplatin in combination with 
bevacizumab.
Clinical experience suggests that bevacizumab is 
not contraindicated in patients on other concomitant 
medications  and  in  particular  enzyme-inducing 
antiepileptic  drugs  (EIAEDs)  and  anticoagulants. 
Dose modifications of bevacizumab are generally not 
required, even when administered to patients taking 
EIAEDs  such  as  phenytoin  or  carbamazepine.32,33 
Additionally,  there  does  not  appear  to  be  an 
appreciable increased risk of hemorrhage (intracranial 
or  extracranial)  with  or  without  concurrent  use  of 
bevacizumab with anticoagulants.46,66 In a retrospective 
review of thromboembolic events and anticoagulation 
in patients with GBM, the investigators concluded 
that  the  use  of  anticoagulants  did  not  lead  to  any 
major hemorrhages and did not appear to prohibit 
the initiation or continuation of bevacizumab therapy 
though the risk of hemorrhage was modestly increased 
(2–3 fold).66
There are, however, specific severe adverse events 
that occur at a relatively low incidence but which 
require  dose  delays  or  cessation  of  bevacizumab. 
Compelling indications for discontinuing bevacizumab 
therapy include intracranial hemorrhage (CTC grade 2 
or higher), bowel perforation, cardiac failure, stroke 
and wound dehiscence,53 and temporary suspension 
of  bevacizumab  is  recommended  4  weeks  prior 
to surgery, as well as in patients with evidence of 
moderate to severe proteinuria or severe hypertension 
that is not controllable with medication.9 The blockade 
of VEGF has been shown to impair wound healing, 
and several studies have indicated a small risk for 
wound dehiscence, either at the site of the craniotomy 
or the central venous line.31–34,45,46,67 In practice, this 
observation mandates that antiangiogenic therapy not 
commence until the craniotomy (or surgical wound) 
is healed, which may require 4 to 6 weeks. Of note, 
there are differences in the frequency of monitoring 
for  select  bevacizumab-related  side  effects  such 
as  proteinuria,  between  clinical  trials  and  current 
clinical practice; based on clinical trial protocols, it 
is recommended that the urine protein be tested either 
with  every  or  every  other  cycle  of  bevacizumab. 
In  patients  with  .2+  proteinuria,  a  24-hour  urine 
collection is suggested to quantify and classify by 
CTC the degree of proteinuria.
A unique challenge in using bevacizumab (as well 
as  other  angiogenic  inhibitors)  for  recurrent  GBM 
is  determining  radiographic  response  as  the  one 
consequence of angiogenic inhibition is a decrease 
in blood brain barrier disruption. As a direct result 
of  the  anti-permeability  effect  of  bevacizumab, 
contrast enhancing tumor conspicuity is diminished 
radiographically.  Therefore  what  appears  to  be  a 
responding  GBM  by  way  of  decrease  in  contrast 
enhancement (and tumor diameters) predominantly 
represents a secondary steroid like effect, a phenom-
enon  termed  a  pseudo  response.  Using  alternative 
MRI sequences such as FLAIR and T2W demonstrate 
typically  little  to  no  change  in  tumor  dimensions 
on  bevacizumab  treatment.  These  findings  suggest 
bevacizumab  is  predominantly  a  cytostatic  agent 
and re-emergence of contrast enhancement appears 
either with discontinuance of bevacizumab or with 
acquisition  of  resistance  to  angiogenic  inhibition. 
The recently published radiology assessment in neuro-
oncology (RANO) criteria attempt to improve upon 
MacDonald  response  criteria  as  well  as  recognize 
post-bevacizumab radiologic changes that confound 
interpretation.36,68
At  present,  there  is  no  consensus  as  to  the 
most  effective  method  for  a  priori  determination 
of  response  to  bevacizumab  treatment.  Common 
practice in patients with recurrent GBM treated with 
bevacizumab involves magnetic resonance imaging 
(MRI) evaluations following 2 cycles of treatment 
and, if stable or responding, after every subsequent 
4 cycles of bevacizumab. Proposed research meth-
ods for evaluating response to bevacizumab include 
assaying for angiogenic factors (eg, serum or urinary 
VEGF, basic fibroblast growth factor, matrix metal-
loproteinase, or urokinase plasminogen activator) or 
ex vivo markers (eg, circulating endothelial cells); 
biopsy analysis (to determine tumor density and drug–
target  interactions);  and  radiographic  assessment 
(calculating fluoro-L-thymidine-PET response, chan-
ges in the apparent diffusion coefficient, or the ratio of 
fluid-attenuated inversion-recovery [FLAIR]   volume 
to contrast-enhancing tumor volume).67,69–73
As  a  secondary  benefit,  bevacizumab  has  been 
shown  to  decrease  both  tumoral  and  peritumoral 
edema in patients with GBM, thereby reducing the Chamberlain
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requirement for chronic corticosteroid use. Several 
studies have reported that corticosteroid reductions 
were feasible in 33% to 59% of patients with recurrent 
GBM  following  bevacizumab  treatment,32,34,36,46,49,74 
and  2  trials  have  reported  average  corticosteroid 
dose  reductions  of  72%  and  59%,36,74  respectively. 
The ability of bevacizumab-based therapy to reduce 
corticosteroid usage is an important benefit, as chronic 
corticosteroid use in patients with GBM is associated 
with significant morbidity and numerous side effects, 
including a cushingoid pattern of weight gain; hyper-
glycemia,  skin  fragility  and  bleeding;  myopathy; 
lymphopenia; infection; and thromboembolism.75–77
Interestingly,  a  recent  retrospective  analysis  in 
recurrent GBM that compared outcomes in patients 
treated with bevacizumab (n = 44) with those in a 
control group (n = 79) suggested that the effect of 
bevacizumab  is  greater  in  patients  with  advanced 
age.47 In the older cohort of patients ($55 years), 
bevacizumab  treatment  was  associated  with  a 
significant  improvement  in  both  PFS  (P  =  0.02) 
and  OS  (P  =  0.03)  relative  to  the  control  group. 
By  contrast,  no  treatment-related  differences 
in    outcomes  were  observed  in  younger  patients 
(,55 years). The authors hypothesized that this age-
dependent response may be reflective of biological 
differences (eg, VEGF-expression levels) in GB in 
various age groups.47 At a minimum, these results 
support the applicability of bevacizumab for older 
patients  with  GBM,  a  cohort  of  patients  with  the 
highest GBM-related mortality.
Notwithstanding  evidence  of  bevacizumab 
activity in recurrent GBM, not all patients respond to 
treatment, and no biomarkers for patients responsive 
to antiangiogenic therapies have been identified. One 
explanation for the lack of response after bevacizumab 
treatment is that antiangiogenic therapy only treats 
one of several tumor compartments—the angiogenic-
dependent contrast-enhancing component—and does 
not target the highly infiltrative migratory angiogenic-
independent  compartment  (eg,  the  leading  edge 
of  infiltrating  glioma  cells  [FLAIR-defined  tumor 
volume]).53,68 In a retrospective analysis, a diffuse, 
infiltrative  pattern  of  recurrence  was  seen  in  20% 
of  patients  (8/40;  95%  CI,  9%–36%)  treated  with 
salvage bevacizumab for recurrent GBM.78 While the 
authors noted that this pattern of recurrence appears 
to be more prevalent with bevacizumab treatment, 
the analysis, in lacking a control arm, did not provide 
a corresponding baseline value to establish a more 
definitive  association  for  this  recurrence  pattern. 
Two  recently  published  studies,  one  conducted 
retrospectively in the prospective BRAIN trial and the 
other retrospective, suggest that an increase in the non-
contrast enhancing infiltrative GBM compartment is 
not promulgated by bevacizumab treatment but rather 
longer survival and failure of bevacizumab to treat 
this  compartment  are  causative.79,80  Importantly,  in 
a  subset  of  patients  failing  bevacizumab,  the  first 
radiographic  evidence  of  disease  progression  is 
enlargement in the infiltrative non-contrast enhancing 
compartment  that  is  best  visualized  by  comparing 
sequential  FLAIR  MR  images.45,46,51,52,68  However, 
in  the  majority  of  patients  disease  progression  on 
bevacizumab is manifested as the re-emergence of 
contrast  enhancing  tumor. A  recent  study  however 
contends that the majority of patients (75%) failing 
bevacizumab  therapy,  regardless  if  given  upfront 
or  at  recurrence  demonstrate  a  diffuse  pattern  of 
recurrence though the pattern of recurrence does not 
impact  post-bevacizumab  survival.81  The  issue  of 
whether diffuse disease is more common following 
bevacizumab  treatment  remains  controversial. 
It was also postulated that abrupt cessation of anti-
VEGF therapy results in rebound edema and clinical 
deterioration (so-called flare response), however this 
has not been shown in clinical studies evaluating off-
bevacizumab radiographic progression.
Determining treatment options for patients with 
GBM who progress following bevacizumab treatment 
is particularly challenging as at present there is no 
consensus on the optimal treatment. Strategies used 
include continuing bevacizumab and adding another 
agent  for  example  carboplatin  (the  most  common 
strategy), discontinuing bevacizumab and treatment 
with  either  an  investigational  agent  or  alternative 
cytotoxic chemotherapy. In 2 retrospective studies, 
it was observed that patients who progress (after an 
initial response) following frontline treatment with 
a  bevacizumab-containing  regimen  rarely  respond 
to  bevacizumab  plus  an  alternative  chemotherapy 
upon progression—with a reported PFS-6 rate of 2% 
and long-term disease control in 9.5% of patients, 
respectively.46,82 Additional studies have reported that Bevacizumab for recurrent glioblastoma
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patients receiving bevacizumab plus irinotecan or an 
alternative cytotoxic therapy following progression 
on single-agent bevacizumab have poor outcomes—0 
of  19  patients  had  radiographic  responses  in  a 
prospective  phase  2  study,  and  a  median  OS  of 
2.0  months  (range,  1.0–5.0  months)  was  reported 
in a retrospective analysis.36,49 In a recent study of 
35  patients  with  GBM  that  progressed  following 
treatment with bevacizumab and irinotecan, continu-
ous low-dose TMZ was added to bevacizumab and 
irinotecan. The authors concluded that this regimen 
appears to have activity in previously treated GBM 
(partial responses in 11.4%, stable disease $2 months 
in 40%, and a median survival of 5 months [range, 
2–13  months]).83  Further  investigation  is  neces-
sary, however, to confirm these preliminary results. 
Patients  with  GBM  who  progress  after  an  initial 
response  to  bevacizumab  represent  a  particularly 
challenging  patient  population.  These  patients  are 
and will increasingly be offered novel investigational 
treatments such as vascular disrupting agents, thera-
pies  targeting  cell  migration  (Src),  and  alternative 
antiangiogenic therapies (ie, therapeutics that target 
basic fibroblast growth factor [bFGF], stromal cell-
derived factor-1α [SDF1α], Tie2, hepatocyte growth 
factor [HGF], and the c-Met receptor).84
projections
Because of positive clinical results seen in recurrent 
GBM,  bevacizumab  continues  to  be  evaluated  in 
additional  treatment  settings.  Most  notably  in  the 
Dutch BELOP trial and the recently opened EORTC 
trial  (EORTC  2601)  are  prospectively  evaluating 
bevacizumab vs. CCNU (lomustine) vs. combination 
therapy in patients with recurrent GBM that will likely 
define  the  benefit  of  bevacizumab  in  comparison 
to  lomustine,  the  standard  of  care  in  Europe. 
These studies represent the first attempt to confirm 
bevacizumab activity in recurrent GBM in a prospec-
tive randomized trial. In addition, there continues to 
be interest in optimizing bevacizumab by way of part-
nering with another agent. Duke University has pro-
posed a trial of bevacizumab in combination with the 
anti-integrin inhibitor, cilengitide, both as initial ther-
apy for recurrent disease as well as in the challeng-
ing situation of recurrent GBM failing bevacizumab. 
Increasingly investigators are appreciating the need 
for investigational trials in recurrent GBM both for 
patients that are bevacizumab naïve as well as expe-
rienced. There is in addition new studies evaluating 
and comparing bevacizumab with standard treatment 
ie, a nitrosourea in recurrent contrast enhancing WHO 
Grades 2 and 3 gliomas (EORTC TAVAREC trial). 
These new trials in part are based upon retrospective 
studies  of  bevacizumab  for  recurrent  anaplastic 
gliomas.35,46,51,52
Because of the improved radiographic response 
to  bevacizumab  in  recurrent  GBM  relative  to 
historical  treatments  (20%–25%  vs.  5%–6%)  and 
improvement in PFS-6 (40% vs. 15%), it was logical 
that up-front studies of bevacizumab were designed 
and executed.85–87 Early efficacy results in 2 studies 
evaluating  bevacizumab  with  radiotherapy  and 
TMZ  for  the  treatment  of  newly  diagnosed  GBM 
compare favorably to data from a historical EORTC 
(European Organization for Research and Treatment 
of  Cancer)/NCIC  (National  Cancer  Institute  of 
Canada Clinical Trials Group) trial.1,86,87 The study 
by Lai represents the first published such trial using 
bevacizumab in combination with standard up-front 
TMZ treatment for newly diagnosed GBM.85 Using 
an  institutional  control  group  of  patients  treated 
with standard TMZ-based chemoradiation and post-
radiation  TMZ  followed  by  bevacizumab  at  time 
of first recurrence, no difference in OS was seen. 
Notably the study results by Lai with respect to the 
primary endpoint ie, OS were very similar to trials 
using non- bevacizumab containing regimens such as 
poly-ICLC or talampanel.2 These studies suggest that 
an improvement in OS is seen in newly diagnosed 
GBM patients irrespective of the add-on therapy in 
part reflecting the effectiveness of bevacizumab as 
a salvage therapy. The most striking difference in 
bevacizumab  administered  early  (upfront)  vs.  late 
(salvage) is seen in the improvement in median PFS 
(13.6 months vs. 7.6 months). Unclear is whether 
this difference in median PFS is clinically relevant. 
Bevacizumab  mechanistically  acts  in  part  as  a 
permeability modifying agent that decreases tumor 
contrast enhancement, the primary measure of tumor 
response.  Consequently  measuring  radiographic 
response by amount of tumor contrast enhancement 
is  problematic  (eloquently  discussed  in  the  new 
RANO criteria) and is the likely explanation of the Chamberlain
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prolongation of PFS.68 Less clear from the study by Lai 
was whether early bevacizumab compared to delayed 
bevacizumab resulted in an improvement in quality of 
life as no instruments such as neurocognitive testing 
were employed. It is recognized that bevacizumab 
administered  to  patients  with  recurrent  GBM 
regardless of response, benefit from the steroid-like 
effect of bevacizumab permitting steroid withdrawal 
or reduction and improvement or resolution of steroid 
toxicity. The challenge of tumor-related vasogenic 
edema and steroid dependency are more clinically 
relevant in the recurrent GBM setting with potentially 
two exceptions ie, patients with large unresectable 
tumors  that  are  steroid  dependent  and  the  elderly 
with  newly  diagnosed  GBM.  A  prospective  trial 
evaluating quality of life throughout the course of a 
GBM would help clarify these issues. Importantly, 
2  large  phase  3  trials—RTOG-0825  (a  US-based 
study sponsored by the Radiation Therapy Oncology 
Group) and AVAglio (a global study sponsored by 
Roche  Pharmaceuticals)—are  nearing  completion 
and  will  prospectively  evaluate  bevacizumab-
containing  regimens  in  patients  with  newly 
diagnosed  GBM.  The  results  of  these  studies  are 
needed to establish the safety, including the potential 
for  wound-healing  complications,  and  efficacy  of 
combining bevacizumab with radiotherapy and TMZ 
in the frontline setting for newly diagnosed GBM. 
In addition, these studies will answer the question, 
does the timing of bevacizumab treatment (upfront 
at initial diagnosis or at recurrence) matter in the 
management of patients with GBM?
Because  a  secondary  benefit  of  bevacizumab 
therapy  is  a  marked  improvement  of  peritumoral 
edema, leading to reductions in or discontinuance 
of  corticosteroid  use,  bevacizumab  may  also  be 
useful in the management of symptomatic patients 
with suspected pseudo progression   following con-
current  TMZ  and  radiation  for  newly    diagnosed 
GBM,88–90  as  well  as  in  patients  with    inoperable, 
newly  diagnosed  GBM  complicated  by  large 
  corticosteroid-dependent tumor masses.   Additionally, 
there  are  indications  that  bevacizumab  may  be 
beneficial in patients with other brain tumors and 
CNS disorders, such as radiation-induced necrosis 
with mass effect,74,91,92 highly angiogenic non-glioma 
  recurrent primary brain tumors such as meningioma, 
medulloblastoma,  ependymoma,93  oligodendroglial 
tumors,52,94,95  neurofibromatosis  2  (NF2)-related 
vestibular  schwannomas,96  and  radiation-induced 
myelopathy.97
Discussion
treatment of GBM, a malignant disease associated 
with an impoverished survival.89,98 Bevacizumab is 
the  best  characterized  antiangiogenic  therapy  and 
recently received FDA approval as a single agent for 
the treatment of patients with recurrent GBM following 
prior  upfront,  TMZ-based  chemoradiotherapy. 
  Overall,  treatment  with  bevacizumab  in  multiple 
GBM studies appears to be well tolerated with tox-
icity (ie, bleeding, hypertension, wound dehiscence, 
proteinuria, intracranial hemorrhage and thromboem-
bolism), similar to that seen with other solid cancers 
treated with bevacizumab-containing therapies.
Because  of  the  extensive  clinical  experience 
with  bevacizumab,  practical  issues  regarding  its 
administration,  safety  profile,  and  response  to 
treatment have been described.  89,98,99 Not withstanding 
this knowledge, several important questions about 
the  use  of  bevacizumab  in  GBM  still  remain 
unanswered—for example, the optimal therapeutic 
partner,  dosage,  treatment  schedule,  treatment 
duration in responding patients (ie, in the BRAIN 
trial 38% of patients continue on treatment at 1-year 
and  16%  at  2-years)  and  radiographic  response 
criteria of bevacizumab are all unknown, as are the 
treatment options that should be offered to patients 
who progress on bevacizumab-based therapy. Many 
of  these  unanswered  questions  are  addressed  in 
  on-going  clinical  trials  and  results  of  these  trials 
will likely to continue to drive improvements in the 
treatment of patients with GBM.
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